Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's DiseaseTerminated
NCT07348250EARLY_Phase 1Updated Jul 27, 2026
Sponsor: Invicro
Parkinson's Disease (PD) · Parkinson's Disease · Parkinson's Disease (Disorder)
United States
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)Recruiting
NCT06818643Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Advanced Solid Tumors · Malignant Neoplasm
United States, Chile, China, France, Israel +7 more
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Recruiting
NCT06395103Phase 1, Phase 2Updated Jul 27, 2026
Sponsor: Merck Sharp & Dohme LLC
B-cell Acute Lymphoblastic Leukemia · Diffuse Large B-cell Lymphoma · Burkitt Lymphoma · Neuroblastoma
United States, Australia, Belgium, Brazil, Canada +18 more
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Recruiting
NCT06136624Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Prostate Cancer Metastatic
United States, Argentina, Australia, Austria, Brazil +31 more
Sac-TMT for Active TNBC Brain MetastasesNot Yet Recruiting
NCT07458113Phase 2Updated Jul 24, 2026
Sponsor: Yale University
Metastatic Triple Negative Breast Cancers
United States
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Active Not Recruiting
NCT04634877Phase 3Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Endometrial Neoplasms
United States, Argentina, Austria, Belgium, Canada +23 more
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)Recruiting
NCT06445972Phase 1, Phase 2Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal Neoplasms · Esophageal Cancer
United States, Brazil, Chile, China, France +6 more
A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).Recruiting
NCT06655324Phase 1Updated Jul 24, 2026
Sponsor: Merck Sharp & Dohme LLC
Healthy
United States
Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High StatusNot Yet Recruiting
NCT07094893Phase 4Updated Jul 24, 2026
Sponsor: Gruppo Oncologico del Nord-Ovest
Colorectal Cancer
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced SarcomaActive Not Recruiting
NCT04874311Phase 2Updated Jul 24, 2026
Sponsor: Institut Bergonié
Advanced Soft-tissue Sarcoma · Metastatic Soft-tissue Sarcoma
France
Efficacy of Suvorexant on Post-operative Sleep DisturbanceCompleted
NCT05823844Phase 4Updated Jul 23, 2026
Sponsor: Columbia University
Postoperative Insomnia · Postoperative Delirium
United States
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)Not Yet Recruiting
NCT07722611Phase 2, Phase 3Updated Jul 23, 2026
Sponsor: Merck Sharp & Dohme LLC
Polycythemia Vera
Improving Vaccine Acceptance Through EHR Integrated Patient- and Provider-Facing Decision SupportRecruiting
NCT06482450NAUpdated Jul 23, 2026
Sponsor: Johns Hopkins Bloomberg School of Public Health
Vaccine Hesitancy · Vaccine Refusal
United States
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive Not Recruiting
NCT04471974Phase 2Updated Jul 23, 2026
Sponsor: Rahul Aggarwal
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Adenocarcinoma · Metastatic Prostate Small Cell Carcinoma · Stage IV Prostate Cancer AJCC v8
United States
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPDActive Not Recruiting
NCT07016412Phase 2Updated Jul 23, 2026
Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease
United States
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)Terminated
NCT06022757Phase 1, Phase 2Updated Jul 23, 2026
Sponsor: Evopoint Biosciences Inc.
Carcinoma · Squamous Cell Carcinoma of Head and Neck · Urothelial Carcinoma · Prostate Cancer
China
Genitourinary Tumors With Sacituzumab TirumotecanNot Yet Recruiting
NCT07716917Phase 2Updated Jul 23, 2026
Sponsor: Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Papillary Renal Carcinoma · Variant Histology Urothelial Carcinoma
Spain
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2Active Not Recruiting
NCT05911295Phase 3Updated Jul 22, 2026
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Urothelial Carcinoma
United States, Argentina, Australia, Belgium, Brazil +19 more
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsActive Not Recruiting
NCT03485209Phase 2Updated Jul 22, 2026
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Exocrine Pancreatic Cancer · Carcinoma, Squamous Cell of Head and Neck
United States, Canada, France, Germany, Italy +2 more
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal CancerTerminated
NCT05167409Phase 2Updated Jul 22, 2026
Sponsor: University of Colorado, Denver
Microsatellite Stable Metastatic Colorectal Cancer
United States
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)Completed
NCT03924856Phase 3Updated Jul 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Bladder Cancer
United States, Australia, Belgium, Canada, Denmark +17 more
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Active Not Recruiting
NCT02974738Phase 1Updated Jul 22, 2026
Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Advanced Solid Tumors · Solid Tumor · Solid Carcinoma · Solid Tumor, Adult
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)Active Not Recruiting
NCT04895358Phase 3Updated Jul 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms
United States, Argentina, Australia, Austria, Brazil +26 more
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical CancerTerminated
NCT03786081Phase 1, Phase 2Updated Jul 22, 2026
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Cervical Cancer
United States, Belgium, Czechia, Denmark, Ireland +5 more
Pembrolizumab, Olaparib, and Temozolomide for People With GliomaRecruiting
NCT05188508Phase 2Updated Jul 22, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Glioma
United States

Previous page Next page